Research Article

Endogenous Asymmetric Dimethylarginine Pathway in High Altitude Adapted Yaks

Shiro Mizuno, Takeshi Ishizaki, Hirohisa Toga, Akio Sakai, Jainagul Isakova, Elnura Taalaibekova, Zamirbek Baiserkeev, Baktybek Kojonazarov, and Almaz Aldashev

1Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa 920-0293, Japan
2Department of Health Science, Matsumoto University, Matsumoto 390-1295, Japan
3Laboratory of Molecular and Cell Biology, Institute of Molecular Biology and Medicine, 720040 Bishkek, Kyrgyzstan
4Excellence Cluster Cardio-Pulmonary System, Universities of Giessen & Marburg Lung Center, 35392 Giessen, Germany

Correspondence should be addressed to Takeshi Ishizaki; takeshi@kanazawa-med.ac.jp

Received 19 June 2015; Accepted 13 August 2015

Abstract

Hypoxia-induced and high altitude pulmonary hypertension are a major problem in the mountain areas of the world. The asymmetric methylarginines (ADMA) inhibit nitric oxide (NO) synthesis by competing with L-arginine, and high levels of plasma ADMA predict adverse outcomes in pulmonary hypertension. However, little is known about the regulation of the ADMA-NO pathway in animals adapted to high altitudes. We measured the plasma ADMA concentration, endothelial NO synthase (eNOS), dimethylarginine dimethylaminohydrolases (DDAH) protein expression, and DDAH activities in the lungs from yaks. Although the yaks are hypoxemic, cardiac function and pulmonary arterial pressures are almost normal, and we found decreased DDAH expression and activity in association with reduced plasma ADMA concentrations. The eNOS expression was significantly higher in yaks. These results indicate that augmented endogenous NO activity in yaks through the ADMA-DDAH pathway and eNOS upregulation account for the low pulmonary vascular tone observed in high altitude adapted yaks.

1. Introduction

It is well known that endogenous nitric oxide (NO) plays a pivotal role in maintaining the low pulmonary vascular tone patients with pulmonary hypertension [1]. Recent studies imply that asymmetric dimethylarginine (ADMA), an endogenous guanido-substituted analogue of L-arginine, also plays a critical role as a natural inhibitor of nitric oxide synthase (NOS) in the regulation of endogenous NO production. ADMA is synthesized via the methylation of protein arginine residues by the enzyme protein arginine methyltransferase I (PRMT1) [2] and competes with L-arginine for NOS and inhibits NO formation [3]. ADMA is mainly inactivated by dimethylarginine dimethylaminohydrolases (DDAH) by hydrolysis to L-citrulline. Because ADMA is degraded by DDAH, the plasma and tissue levels of ADMA are thought to be regulated by the DDAH activities. Previous studies showed that the overexpression of DDAH reduced tissue and plasma levels of ADMA which was associated with an increased production of NO, a reduction in systemic vascular resistance, and reduced atherosclerosis in transgenic mice [4, 5]. The DDAH activity also has a protective role in insulin resistance [6, 7] and progression of chronic kidney disease, which are both associated with reduced level of ADMA and increased endogenous NO production [8, 9]. A reduced expression or pharmacological inhibition of DDAH results in elevated levels of ADMA associated with decreased reaction of NO-mediated vasodilation [10] which supports the idea that local tissue DDAH activity plays an important role in the maintenance of vascular tone and NOS activity via ADMA production. Notably, the plasma level of ADMA not only is a simple biomarker of many diseases, but also could be of functional importance and a key substance, especially in the progression of cardiovascular and metabolic diseases associated with endothelial dysfunction [11, 12]. Increased plasma levels of ADMA may contribute to impaired NO
synthesis leading to atherosclerosis, progression of cardiovascular disease, diabetes mellitus, and chronic renal disease [13, 14]. A functional role of plasma levels of ADMA has been attributed to endothelial cell dysfunction in pulmonary hypertension [15–20], cardiovascular disease, chronic renal disease, and portal hypertension in liver cirrhosis [21]. In patients with pulmonary hypertension, elevated levels of ADMA are closely correlated with decreased exercise tolerance [19], the severity of pulmonary hypertension, and a poor prognosis [15, 18].

Pulmonary hypertension is a common complication among highlanders and animals that live at high altitudes. Chronic exposure to a decreased oxygen pressure causes chronic hypoxemia and secondary pulmonary hypertension and pulmonary vascular remodeling in human and animals [22, 23]. After several weeks of exposure to high altitude, lowlanders develop pulmonary hypertension, which is not completely reversed by supplemental oxygen [24], suggesting development of vascular remodeling of the lung [25]; this vascular remodeling is also related to a decreased activity of NOS [26, 27]. However, high altitude adapted animals, such as yak, llama, and the Tibetan sheep, have low pulmonary vascular tone, normal right ventricular function, and also a decreased hypoxic pulmonary vasconstrictor response [28–31]. We previously reported an enhanced effect of NOS inhibition in the yak pulmonary circulation [32], consistent with an augmented production of NO in yaks living at high altitude.

Because of these previous findings, we hypothesized that elevated activity of DDAH in the lung tissue, which suppresses ADMA expression, could be a regulatory factor of the pulmonary vascular tone in yaks. In order to address this hypothesis, we assessed eNOS and DDAH protein expression and activity of DDAH of lung tissues obtained from yaks living at high altitude and we also measured nitrites and ADMA concentrations in the yak plasma.

2. Materials and Methods

2.1. Animals. Young (2 years old) male yaks with an estimated weight of 200 kg were used for the experiment. Yaks were living at Archaly (2900–3000 m above sea level). Male bovines (2 years old) with an estimated weight of 200 kg were used as a control group. The cattle were living in Bishkek (760 m above sea level).

2.2. Hemodynamic Studies. A balloon-tipped pulmonary arterial catheter was inserted percutaneously into a right internal jugular vein and advanced to the pulmonary artery for measurement of pulmonary artery pressure (PPA) and pulmonary capillary wedge pressure (PWP). A plastic catheter was placed percutaneously into the right internal jugular artery to monitor the systemic arterial pressure and heart rate (HR). Arterial oxygen saturation (SaO₂) was measured by pulse oximetry. The cardiac output (CO) was measured by the thermodilution method using a Swan–Ganz catheter and a cardiac output computer (Vigilance).

2.3. Western Blot Analysis. Lung protein extracts were prepared for Western blot analysis by homogenization of tissue samples and the protein concentration was determined by the Bradford method (BioRad). Homogenates (100 μg for eNOS, 20 μg for DDAH I, or 50 μg for DDAH II) were separated by SDS-PAGE (7.5% for eNOS, 12% for DDAH I and DDAH II) and then transferred to nitrocellulose membranes (BioRad). Blots were blocked with TBS buffer (50 mmol/L Tris–HCl, pH 7.4, 0.15 mol/L NaCl, 0.1% Tween-20) plus 2% (wt/vol) BSA or 5% (wt/vol) nonfat milk for 1 hour at room temperature and then incubated for 1 hour at room temperature with an eNOS monoclonal antibody (1:500 dilution in TBS plus BSA, Transduction Laboratories), a DDAH I monoclonal antibody, or a DDAH II polyclonal antibody. Immunoreactive proteins were detected following incubation with a peroxidase-conjugated antibody and enhanced chemiluminescence (Amersham). The relative protein expression was quantified by densitometric analysis.

2.4. Measurement of DDAH Activity. Freshly prepared lung tissue of yaks and cows was homogenized with sodium phosphate buffer, pH 6.5, at 4°C in a glass homogenizer. The homogenate was centrifuged at 10,000 g for 30 min to obtain the supernatant. Briefly, the lysate was incubated with 4 mmol/L ADMA and 0.1 mol/L sodium phosphate buffer (pH 6.5) in a total volume of 0.5 mL for 2 hours at 37°C. The reaction was stopped by the addition of an equal volume of 10% trichloroacetic acid, and the supernatant was boiled with diacetyl monoxide (0.8% in 5% acetic acid) and antipyrine (0.5% in 50% sulfuric acid). The amounts of L-citrulline formed were determined by spectrophotometric analysis at 466 nm. As the assay blank, the enzyme preparations heated in a boiling water bath were subjected.

2.5. Measurement of Plasma Nitrite, ADMA, and Endothelin-1 (ET-1) Concentration. The concentrations of plasma ADMA were measured using an ELISA immunoassay kit according to the manufacture’s protocol (DLD Diagnostika Gmbh, Germany). The nitrite concentration in plasma was measured using the Griess reagent system from Promega (USA), and the plasma concentrations of ET-1 were determined by high power liquid chromatography (HPLC).

2.6. Statistical Analysis. The results are expressed as mean ± SD. The statistical analysis was performed using Student’s t-test. Comparisons were considered statistically significant at P < 0.05.

3. Results

3.1. Parameters of Pulmonary Hemodynamics in High Altitudes Yaks. Pulmonary hemodynamic data in high altitudes yaks are summarized in Table 1. Although the arterial oxygen saturation of yaks is apparently below normal, the pulmonary hemodynamics including the mean pulmonary arterial pressure and the PVR were almost normal.

3.2. Nitrates, ADMA, and ET-1 Concentrations in Yaks and Bovines. Although the average nitrate concentration is slightly higher in yaks when compared to that in the bovine,
there were no significant differences in serum nitrates concentrations between bovines and yaks. The serum levels of ET-1 in yaks were significantly increased compared with that from bovines, and the serum ADMA levels were significantly decreased compared with that from bovines (Figures 1(a), 1(b) and 1(c)).

3.3. eNOS, DDAH Protein Expression, and DDAH Enzyme Activity. The Western blot analysis of lung homogenates showed that the expression of the eNOS protein in the lungs from yaks was markedly higher when compared with that from bovines, and both the DDAH I and DDAH II protein expression were apparently increased in the lungs from yaks when compared with those from bovines (Figure 2).

The protein DDAH expression and the DDAH enzyme activity in the lungs from yaks were significantly higher, roughly twice, as high when compared with the bovine samples (Figure 3).

4. Discussion

Our present experiments confirmed our previous studies showing augmented NO activity in yaks living at high altitudes. We had previously inferred this result from data obtained following the administration of the NOS inhibitor, N\textsuperscript{ \textsubscript{ω} }-nitro-L-arginine (NLA) [32]. We now find increased DDAH expression and activity associated with low levels of plasma ADMA in yaks. The increased DDAH protein
expression and DDAH activity in the lungs from yaks is in line with previous findings showing regulatory effects of DDAH expression in regard to the NO-ADMA-DDHA pathway [33]. Impaired DDAH activity results in the accumulation of ADMA in animals [34]. Our results of increased expression and activity of DDAH in the lungs from yak raise the possibility that the low pulmonary vascular tone in yaks living at high altitudes is derived from enhanced NO production and NOS activity due to decreased expression of the endogenous NOS inhibitor in the lung tissue. In addition, our findings of decreased levels of ADMA in plasma from yaks support a role of ADMA as a biomarker of pulmonary pressure regulation [15, 35].

The lungs are thought to be a major source of NOS and ADMA [36]. Many previous studies have shown increased plasma levels of ADMA in patients with various forms of PAH, including idiopathic PAH [15, 16], PAH associated with chronic thromboembolism [18], sickle cell disease-related PH [20, 37], PAH associated with collagen vascular disease [19], and congenital heart disease [17]. It is possible that shear stress-induced PRMT activity [38] and downregulation of DDAH induced by alveolar hypoxia [39] could be responsible for the increased plasma ADMA expression. However, because of the decreased SaO$_2$ and the normal pulmonary arterial pressure of the yaks, we cannot explain the increased expression of DDAH in our study as caused by pulmonary vascular shear stress in the yaks. At present, the precise mechanism of high DDAH expression in yaks remains uncertain, and we speculate that an evolutionary process of yaks living at high altitudes has altered the regulation of the ADMA-DDAH pathway in such a way as to provide protection against PAH via augmented local activation of NO production in the lungs.

Previous results showing decreased eNOS expression in PAH patients and increased levels of ADMA [18] suggest that circulating ADMA is a potential negative regulator of eNOS expression in pulmonary arteries. Although it has not been investigated whether circulating ADMA influences eNOS expression, the inhibitory effect of ADMA in the pulmonary vascular tone may be attenuated by the increased NOS protein expression as we found in our yak study. There is evidence that systemic infusion of ADMA also increases the systemic vascular resistance and decreases the cardiac output in humans [40] and this finding supports the role of plasma ADMA levels in the pulmonary circulation of yaks as an adaptive mechanism.

Despite the lower ADMA plasma levels and increased eNOS expression in yaks, we could not find significant differences in nitrate concentrations between yaks and bovines (Figure 1(a)). This discrepancy may be explained by the decreased oxygen concentration in the lungs and perhaps by different diets of the two animal species. Our result showing higher levels of ET-1 in yaks is consistent with an alveolar hypoxia- or hypoxemia-induced activation of hypoxia-induced factor alpha (HIF-1$\alpha$) and ET-1 pathways in the yaks [41]. Because oxygen is necessary for NO production by NOS, alveolar hypoxia will result in a reduced activity of NOS [11]. In addition, it is known that exogenous food-derived nitrate could also affect plasma nitrate levels, in addition to the L-arginine-NO pathway [1].
In conclusion, the results of this study show augmented expression of DDAH expression and activity associated with reduced levels of plasma ADMA in yaks. The results of augmented activity of NOS in yaks could be explained by the ADMA-DDAH-NO pathway. However, further investigation regarding the plasma ADMA and DDAH activity of the adapted animals and/or humans living at high altitudes is necessary to determine whether decreased plasma ADMA levels impact the eNOS expression in the lung and the pulmonary arterial pressure.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**Acknowledgments**

This study was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (nos. 16406026 and 24591144). The authors wish to thank Professor Norbert F. Voelkel, Virginia Commonwealth University, Richmond, VA, USA, for his critical reading of this paper.

**References**

[1] M. Bueno, J. Wang, A. L. Mora, and M. T. Gladwin, "Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics," *Antioxidants & Redox Signaling*, vol. 18, no. 14, pp. 1797–1809, 2013.

[2] J. Tang, A. Frankel, R. J. Cook et al., "PRMTi is the predominant type I protein arginine methyltransferase in mammalian cells," *The Journal of Biological Chemistry*, vol. 275, no. 11, pp. 7723–7730, 2000.

[3] P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, "Accumulation of an endogenous inhibitor of nitric oxide synthase in chronic renal failure," *The Lancet*, vol. 339, no. 8793, pp. 572–579, 1992.

[4] H. Dayoub, V. Achan, S. Adimoolam et al., "Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence," *Circulation*, vol. 108, no. 24, pp. 3042–3047, 2003.

[5] J. Jacobi, R. Maas, A. J. Cardounel et al., "Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine," *The American Journal of Pathology*, vol. 176, no. 5, pp. 2559–2570, 2010.

[6] K. Srdow, C. E. Mondon, J. Schrader, H. Konishi, and J. P. Cooke, "Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 4, pp. 692–697, 2008.

[7] Y. T. Ghebremaryam, K. Yamada, J. C. Lee et al., "FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats," *PLoS ONE*, vol. 8, no. 4, Article ID e60653, 2013.

[8] S. Ueda, S.-I. Yamagishi, Y. Matsumoto et al., "Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD)," *Life Sciences*, vol. 84, no. 23–24, pp. 853–856, 2009.

[9] G.-F. Chen, N. C. Moningka, J. M. Sasser et al., "Arginine and asymmetric dimethylarginine in puromycin aminonucleoside-induced chronic kidney disease in the rat," *American Journal of Nephrology*, vol. 35, no. 1, pp. 40–48, 2012.

[10] R. J. MacAllister, H. Parry, M. Kimoto et al., "Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase," *British Journal of Pharmacology*, vol. 119, no. 8, pp. 1533–1540, 1996.

[11] J. Pernow and C. Jung, "Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginase steal?" *Cardiovascular Research*, vol. 98, no. 3, pp. 334–343, 2013.

[12] H. Konya, M. Miuchi, K. Satani et al., "Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus," *World Journal of Experimental Medicine*, vol. 5, no. 2, pp. 110–119, 2015.

[13] F. Abbasi, T. Asagmi, J. P. Cooke et al., "Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus," *The American Journal of Cardiology*, vol. 88, no. 10, pp. 1201–1203, 2001.

[14] H. Kielstein, M. Sutharalingam, R. Perthel et al., "Role of the endogenous nitric oxide inhibitor ADMA and BDNF in depression and behavioural changes: clinical and preclinical data in chronic kidney disease," *Nephrology Dialysis Transplantation*, 2015.

[15] S. Pullamsetti, L. Kiss, H. A. Ghofrani et al., "Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension," *The FASEB Journal*, vol. 19, no. 9, pp. 1175–1177, 2005.

[16] J. T. Kielstein, S. M. Bode-Böger, G. Hesse et al., "Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 7, pp. 1414–1418, 2005.

[17] C. L. Cua, L. K. Rogers, L. G. Chicoine et al., "Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine," *European Journal of Pediatrics*, vol. 170, no. 7, pp. 859–863, 2011.

[18] N. Skoro-Sajer, F. Mittermayer, A. Panzenboeck et al., "Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension," *American Journal of Respiratory and Critical Care Medicine*, vol. 176, no. 11, pp. 1154–1160, 2007.

[19] T. Dimitroula, G. Giannakoulos, T. Sfetsios et al., "Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension," *Rheumatology*, vol. 47, no. 11, pp. 1682–1685, 2008.

[20] G. J. Kato, Z. Wang, R. F. MacHado, W. C. Blackwelder, J. G. Taylor VI, and S. L. Hazen, "Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death," *British Journal of Haematology*, vol. 145, no. 4, pp. 506–513, 2009.

[21] N. Lünburg, L. Harbaum, and J. K. Hennigs, "The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases," *BioMed Research International*, vol. 2014, Article ID 501612, 11 pages, 2014.

[22] R. F. Grover, "Pulmonary circulation in animals and man at high altitude," *Annals of the New York Academy of Sciences*, vol. 127, no. 1, pp. 632–639, 1965.

[23] M. Maggiorini and F. Léon-Velarde, "High-altitude pulmonary hypertension: a pathophysiological entity to different diseases," *European Respiratory Journal*, vol. 22, no. 6, pp. 1019–1025, 2003.

[24] B. M. Groves, J. T. Reeves, J. R. Sutton et al., "Operation Everest II: elevated high-altitude pulmonary resistance unresponsive to
oxygen,” *Journal of Applied Physiology*, vol. 63, no. 2, pp. 521–530, 1987.

[25] R. Hainsworth and M. J. Drinkhill, “Cardiovascular adjustments for life at high altitude,” *Respiratory Physiology & Neurobiology*, vol. 158, no. 2-3, pp. 204–211, 2007.

[26] F. León-Velarde and O. Mejía, “Gene expression in chronic high altitude diseases,” *High Altitude Medicine and Biology*, vol. 9, no. 2, pp. 130–139, 2008.

[27] S. Mizuno, M. Kadowaki, Y. Demura, S. Ameshima, I. Miyamori, and T. Ishizaki, “p42/44 Mitogen-activated protein kinase regulated by p53 and nitric oxide in human pulmonary arterial smooth muscle cells,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 31, no. 2, pp. 184–192, 2004.

[28] P. Harris, D. Heath, P. Smith et al., “Pulmonary circulation of the llama at high and low altitudes,” *Thorax*, vol. 37, no. 1, pp. 38–45, 1982.

[29] I. S. Anand, E. Harris, R. Ferrari, P. Pearce, and P. Harris, “Pulmonary haemodynamics of the yak, cattle, and cross breeds at high altitude,” *Thorax*, vol. 41, no. 9, pp. 696–700, 1986.

[30] A. G. Durmowicz, S. Hofmeister, T. K. Kadyraliev, A. A. Aldashev, and K. R. Stenmark, “Functional and structural adaptation of the yak pulmonary circulation to residence at high altitude,” *Journal of Applied Physiology*, vol. 74, no. 5, pp. 2276–2285, 1993.

[31] T. Koizumi, Z. Ruan, A. Sakai et al., “Contribution of nitric oxide to adaptation of tibetan sheep to high altitude,” *Respiratory Physiology and Neurobiology*, vol. 140, no. 2, pp. 189–196, 2004.

[32] T. Ishizaki, T. Koizumi, Z. Ruan, Z. Wang, Q. Chen, and A. Sakai, “Nitric oxide inhibitor altitude-dependently elevates pulmonary arterial pressure in high-altitude adapted yaks,” *Respiratory Physiology and Neurobiology*, vol. 146, no. 2-3, pp. 225–230, 2005.

[33] W. Janssen, S. S. Pullamsetti, J. Cooke, N. Weissmann, A. Guenther, and R. T. Schermuly, “The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis,” *The Journal of Pathology*, vol. 229, no. 2, pp. 242–249, 2013.

[34] K. Y. Lin, A. Ito, T. Asagami et al., “Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase,” *Circulation*, vol. 106, no. 8, pp. 987–992, 2002.

[35] L. J. Millatt, G. S. J. Whitley, D. Li et al., “Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension,” *Circulation*, vol. 108, no. 12, pp. 1493–1498, 2003.

[36] P. Bulau, D. Zakrzewicz, K. Kitowska et al., “Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA,” *The American Journal of Physiology—Lung Cellular and Molecular Physiology*, vol. 292, no. 1, pp. L18–L24, 2007.

[37] P. P. Landburg, T. Teerlink, E. J. van Beers et al., “Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension,” *Haematologica*, vol. 93, no. 9, pp. 1410–1412, 2008.

[38] T. Osanai, M. Saitoh, S. Sasaki, H. Tomita, T. Matsunaga, and K. Okumura, “Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells,” *Hypertension*, vol. 42, no. 5, pp. 985–990, 2003.

[39] F. I. Arrigoni, P. Vallance, S. G. Haworth, and J. M. Leiper, “Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia,” *Circulation*, vol. 107, no. 8, pp. 1195–1201, 2003.